Dataset for 'Immunogenicity and efficacy of XBB.1.5 rS vaccine against EG.5.1 variant of SARS-CoV-2 in Syrian hamsters'
Description
This dataset contains the raw data supporting all main and supplementary figures used in the manuscript "Immunogenicity and efficacy of XBB.1.5 rS vaccine against EG.5.1 variant of SARS-CoV-2 in Syrian hamsters," published in Journal of Virology (JVI). The data includes measurements of humoral and cellular immune responses in Syrian hamsters following immunization with the nanoparticle recombinant Spike (S) protein-based COVID-19 vaccine (Novavax, Inc.) from different variants. It also includes data comparing the efficacy of the updated monovalent XBB.1.5 variant vaccine to previous COVID-19 vaccines in inducing XBB.1.5 and EG.5.1 neutralizing antibodies and in protecting against a challenge with the EG.5.1 variant of SARS-CoV-2.
Files
Steps to reproduce
Refer to the "Materials and Methods" section of the publication.
Institutions
- Novavax Inc
- Washington University in St. Louis
- Emory University
Categories
Funders
- National Institute of Allergy and Infectious DiseasesUnited StatesGrant ID: Centers of Excellence for Influenza Research and Response (CEIRR) contract 75N93021C00016
Additional Metadata for Digital Commons Data@Becker
| Keywords | SARS-CoV-2 Variants, Syrian Hamsters, Immunogenicity, Efficacy, Nanoparticle Protein-based Vaccine, Vaccine-induced Protection, Cross-reactive Immunity, Heterologous Infection |